Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva de Jongh

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Elife|November 26, 2020
A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based studyJoachim Linssen, Anthony Ermens, Marvin Berrevoets, et al.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Cancers|October 13, 2021
Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled TrialDaniëlle E J Starreveld, Laurien A Daniels, Jacobien M Kieffer, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Haematologica|September 18, 2025
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemiaKathelijn Verdeyen, Tom Reuvekamp, Walter J F M Van der Velden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Elife|November 26, 2020
A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based studyJoachim Linssen, Anthony Ermens, Marvin Berrevoets, et al.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Cancers|October 13, 2021
Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled TrialDaniëlle E J Starreveld, Laurien A Daniels, Jacobien M Kieffer, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Haematologica|September 18, 2025
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemiaKathelijn Verdeyen, Tom Reuvekamp, Walter J F M Van der Velden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Haematologica|April 16, 2026
Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL studyMarie José Kersten, Martin Dreyling, Kim M Linton, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 2